Global Leading Market Research Publisher QYResearch announces the release of its latest report “Oligonucleotide and Peptide Synthesis – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Oligonucleotide and Peptide Synthesis market, including market size, share, demand, industry development status, and forecasts for the next few years.
For biopharmaceutical companies, contract research organizations, and academic research institutions, the ability to produce custom-designed nucleic acids and peptides with high purity, sequence accuracy, and scalable yield has become essential to modern drug discovery and development. Traditional chemical synthesis methods, while foundational, often struggle to meet the demands of increasingly complex therapeutic modalities—including antisense oligonucleotides, RNA interference (RNAi) therapeutics, mRNA vaccines, and peptide-based drugs—that require precise sequence control, minimal impurities, and production capacity sufficient for clinical and commercial supply. Oligonucleotide and peptide synthesis addresses these challenges through cornerstone technologies that enable the in vitro construction of nucleic acid fragments and peptide chains via chemical or enzymatic methods. Oligonucleotide synthesis, typically achieved through solid-phase synthesis, produces custom-designed DNA or RNA sequences for applications in gene editing, molecular diagnostics, antisense therapeutics, RNA interference, and vaccine development. Peptide synthesis, primarily via solid-phase peptide synthesis (SPPS) or liquid-phase methods, creates tailored peptides used in drug discovery, protein structure-function studies, vaccine design, and advanced biomaterials. The global market for oligonucleotide and peptide synthesis, valued at US$1,085 million in 2025, is projected to reach US$1,633 million by 2032, growing at a compound annual growth rate (CAGR) of 6.1%—reflecting the accelerating transition of these technologies from research tools to critical drivers of clinical translation and large-scale pharmaceutical manufacturing.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6097933/oligonucleotide-and-peptide-synthesis
Market Segmentation and Technology Architecture
The biopharmaceutical synthesis market is structured around synthesis type and end-user domain, each with distinct technical requirements:
- By Type (Synthesis Technology): The market segments into Oligonucleotide Synthesis and Peptide Synthesis. Oligonucleotide Synthesis currently accounts for the largest and fastest-growing segment, driven by the commercial success of nucleic acid-based therapeutics including antisense drugs (e.g., nusinersen, eteplirsen), RNAi therapeutics (e.g., patisiran, givosiran), and the unprecedented scale of mRNA vaccine production for COVID-19 and other infectious diseases. Solid-phase synthesis with phosphoramidite chemistry remains the dominant methodology, with increasing adoption of enzymatic synthesis for longer sequences and specialized applications. Peptide Synthesis maintains a significant market presence, with solid-phase peptide synthesis (SPPS) as the standard for therapeutic peptides (e.g., liraglutide, semaglutide), peptide-based drugs, and custom peptides for research applications.
- By Application (End-User): The market segments into Biotech Companies and Academic Scientific Research Institutions. Biotech Companies currently account for the larger market share, driven by the commercial development and manufacturing of oligonucleotide and peptide therapeutics, diagnostic reagents, and custom synthesis services for drug discovery programs. Academic and Research Institutions represent a significant and stable segment, supporting foundational research in molecular biology, genetics, and drug discovery.
Competitive Landscape and Recent Industry Developments
The competitive landscape features a mix of global life science tools leaders, specialized oligonucleotide and peptide synthesis providers, and contract development and manufacturing organizations (CDMOs). Key players profiled include Thermo Fisher Scientific, Merck, Azenta Life Sciences, BBI Life Sciences, TriLink BioTechnologies, Aurigene Pharmaceutical Services, Integrated DNA Technologies (IDT), Cusabio, Macrogen, Synbio Technologies, Eurogentec, WuXi TIDES, Genscript, Abace Biotechnology, Tsingke, Guangzhou RiboBio, Atantares, Wuhan GeneCreate Biological Engineering, Beyotime, General Biol, and Veliterbio. A significant trend observed over the past six months is the accelerated capacity expansion for commercial-scale oligonucleotide manufacturing. Leading CDMOs have announced multi-million dollar investments in new production facilities capable of multi-kilogram to metric ton-scale synthesis to meet anticipated demand for approved and pipeline nucleic acid therapeutics.
Additionally, the market has witnessed notable advancement in manufacturing process efficiency and impurity control. Next-generation synthesis platforms incorporating advanced coupling chemistries, real-time monitoring, and automated purification systems have achieved yield improvements of 20-30% and impurity reductions of 50% compared to conventional methods—critical for meeting the purity specifications required for therapeutic applications.
Exclusive Industry Perspective: Divergent Requirements in Oligonucleotide vs. Peptide Manufacturing
A critical analytical distinction emerging within the biopharmaceutical manufacturing market is the divergence between requirements for oligonucleotide synthesis versus peptide synthesis at commercial scale. In oligonucleotide manufacturing, the emphasis is on sequence length fidelity, impurity control (particularly shortmer deletions and phosphorothioate modifications), and scale-up capability. Therapeutic oligonucleotides typically range from 15-30 nucleotides, requiring precise control of each coupling step to achieve >98% full-length product. According to recent industry data, the global oligonucleotide synthesis market has grown at a compound annual rate exceeding 15% over the past five years, driven by the increasing number of approved nucleic acid drugs and advancing pipeline candidates.
In peptide manufacturing, requirements shift toward amide bond formation efficiency, difficult sequence handling, and impurity management. Therapeutic peptides range from 20-40 amino acids, with challenges including aggregation-prone sequences, side-chain protection strategies, and controlling racemization during synthesis. Solid-phase peptide synthesis with automated systems remains standard, with increasing adoption of continuous manufacturing approaches for large-scale production. Recent case studies from peptide drug manufacturers demonstrate that advanced SPPS platforms with in-line analytics have reduced purification load by 30-40% through improved crude purity, significantly reducing downstream processing costs.
Technical Innovation and Scale-Up Challenges
Despite significant advances in synthesis technology, the nucleic acid and peptide industries continue to navigate critical technical and manufacturing challenges. Scale-up remains a primary challenge for oligonucleotide synthesis, with typical yields per synthesis cycle ranging from grams to hundreds of grams in conventional platforms. Emerging technologies including continuous flow synthesis, enzyme-based synthesis, and novel solid supports are addressing scale limitations, with pilot-scale continuous platforms demonstrating 5-10x productivity improvements over batch processes.
Another evolving technical frontier is the development of novel chemistries and modifications for therapeutic applications. Modified oligonucleotides incorporating phosphorothioate linkages, 2′-O-methyl, and locked nucleic acid (LNA) chemistries require specialized synthesis conditions that impact yield and impurity profiles. Similarly, peptide synthesis for cyclic peptides, stapled peptides, and conjugates requires specialized chemistries and purification strategies.
Market Dynamics and Growth Drivers
The precision medicine sector is benefiting from several structural trends supporting synthesis market growth. The commercial success and expanding pipeline of nucleic acid therapeutics (antisense, RNAi, mRNA) creates sustained demand for custom oligonucleotide synthesis. The growth of peptide-based therapeutics, including GLP-1 agonists for diabetes and obesity (e.g., semaglutide), drives peptide synthesis demand. Advances in gene editing technologies (CRISPR-Cas9) require synthetic guide RNAs (gRNAs) and donor templates for research and therapeutic applications. Additionally, the expansion of personalized medicine and companion diagnostics drives demand for custom oligonucleotide probes and primers.
Conclusion
The global oligonucleotide and peptide synthesis market represents a critical enabling technology for modern biopharmaceutical development and manufacturing, transforming from research tools to commercial-scale production platforms. As nucleic acid therapeutics advance through clinical development and commercial adoption, as peptide-based drugs address major chronic diseases, and as precision medicine expands, the demand for high-quality, scalable synthesis capabilities will continue to accelerate. The forthcoming QYResearch report provides comprehensive segmentation analysis, regional market sizing, technology assessments, and strategic profiles of key manufacturers, equipping stakeholders with actionable intelligence to navigate this dynamic and rapidly growing biopharmaceutical manufacturing market.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp








